Skip to content Skip to footer
Subscribe Now
NEWS

Median Technologies Receives the US FDA’s 510(k) Clearance for eyonis LCS for Lung Cancer Detection and Diagnosis

Shots: The US FDA has granted 510(k) clearance to eyonis Lung Cancer Screening (LCS), an AI/ML-powered CADe/CADx software, to detect & diagnose lung cancer eyonis LCS analyzes LDCT imaging to help radiologists detect & characterize pulmonary nodules, enabling earlier diagnosis; in testing it showed 93.3% sensitivity, 92.4% specificity & 99.9% NPV, minimizing false positives &…
February 9, 2026

Read more

NEWS

Adaptive Biotechnologies and Pfizer Sign Rheumatoid Arthritis TCR Target Discovery and Immune Data Licensing Deals

Shots: Adaptive has entered into 2 non-exclusive agreements with Pfizer, combining its T-cell receptor (TCR) discovery & immune receptor antigen-mapping platform to support Pfizer’s research across autoimmune & other disease areas As per the target discovery deal, Adaptive will identify disease-specific TCR targets in rheumatoid arthritis from Pfizer clinical samples, while Pfizer will lead development…
December 16, 2025

Read more

TOP 20

Top 20 Countries in Health Innovation in 2025 

Shots:  Harnessing in-depth research and data-driven insights, PharmaShots unveils its definitive report on the Top 20 Countries in Healthcare Innovation 2025, a comprehensive guide to the nations setting global benchmarks in healthcare advancement  Through a meticulous blend of quantitative and qualitative analysis, PharmaShots delved into the multifaceted dimensions of healthcare innovation, spotlighting emerging trends such…
November 6, 2025

Read more

NEWS

insitro and Bristol Myers Squibb Collaborate to Advance Drug Discovery for Amyotrophic Lateral Sclerosis (ALS)

Shots: insitro & BMS have extended their 5yr. collaboration (2020) to discover novel small molecule therapies for ALS using insitro’s AI-enabled ChemML platform The 1yr. extension will focus on developing therapies for a novel ALS target identified preclinically, with insitro receiving ~$20M in new funding & remaining eligible for discovery, development, regulatory, & commercial milestones…
October 15, 2025

Read more

EVENTS

Post Conference Highlights: Peptides & Complex Generics Symposium 2025

Day 1 Breakdown The #PCG2025 Symposium commenced on an inspiring note, setting the stage for two days of insightful discussions, collaborations, and knowledge exchange. Opening Session Dr. Ratnesh Jain, Founder & Director, Mumbai Cluster, delivered the inaugural address, sharing his vision of bringing together pharma professionals, R&D experts, CXOs, and academicians to accelerate advancements in…
September 29, 2025

Read more

NEWS

Variational AI Collaborates with Merck to Develop Small Molecule Therapeutics

Shots: Variational AI has entered into a collaboration with Merck to design and optimize novel small molecule candidates against two undisclosed targets using Variational AI’s Enki platform As per the deal, Variational AI will leverage its fine-tuned Enki platform trained on Merck’s proprietary data to generate & optimize small-molecule candidates for Merck’s targets, with Merck…
September 24, 2025

Read more

CXO TALKS

CXO Talks: Colin Banas from DrFirst in an Illuminating Conversation with PharmaShots 

In the CXO Talks podcast, PharmaShots engaged in a riveting dialogue exchange with Colin Banas, Chief Medical Officer at DrFirst. Colin highlights the evolution of DrFirst from becoming a leader in the e-prescribing space to an end-to-end medication management company  Colin talks about its collaborators, Wise Hospice Options, achieving a new milestone by reducing the…
May 12, 2025

Read more

Thoughtspot_Saurabh_Chaubey
THOUGHTSPOT

Role of Digital Twin Technology in Healthcare

Shots:  Developments in healthcare technologies are setting new standards at present and encouraging exploration into emerging technologies to advance care and enhance the lives of patients globally  Digital Twins are virtual replicas of objects, individuals, or systems spanning their life cycles  The article introduces the role of digital twins in the healthcare system, the advantages,…
March 19, 2025

Read more

J&J & Nosis Bio
NEWS

Nosis Biosciences Partners with Janssen Biotech for Cell-Targeted RNA Drugs

Shots: Nosis Biosciences has entered into a strategic collaboration with Janssen Biotech (subsidiary of J&J) to design & develop cell-targeted RNA medicines The collaboration leverages J&J’s drug discovery & clinical expertise as well as Nosis’ Connexa platform to design drugs with extra-hepatic access to multiple & hard-to-target cell types involved in chronic diseases …
March 12, 2025

Read more

Load more